Caspofungin therapy in immunocompromised children and neonates

References

• Steinbach WJ, Walsh TJ. Mycoses in pediatric patients. Infect. Dis. Clin. North Am.20, 663–678 (2006).
   PubMed Web of Science ®Google Scholar
• Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant.36, 621–629 (2005).
   PubMed Web of Science ®Google Scholar
• Groll AH, Lerhrnbecher T. New antifungal drugs and the pediatric cancer patient: current status of clinical development. Klin. Pediatr.217, 158–168 (2005).
   PubMedGoogle Scholar
• Castagnola E, Bagnasco F, Faraci M et al. Incidence of bacteremia and invasive mycoses in children undergoing allogeneic hematopoietic stem cell transplantation: a single center experience. Bone Marrow Transplant.41, 339–347 (2008).
   PubMed Web of Science ®Google Scholar
• Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis.33, 1529–1535 (2001).
   PubMed Web of Science ®Google Scholar
• Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med.113, 294–299 (2002).
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Eng. J. Med.347, 2020–2029 (2002).
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G et al. Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for the treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis.39, 1563–1571 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Eng. J. Med.351, 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Product information. Cancidas (caspofungin). Merck and Co., Whitehouse Station, NJ, USA (2009).
   Google Scholar
• Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol.35, 79–86 (1997).
   PubMedGoogle Scholar
• Georgopapadakou NH. Update on antifungals targeted on the cell wall: focus on β-1,3-glucan synthase inhibitors. Expert Opin. Investig. Drugs10, 269–280 (2001).
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet362, 1142–1151 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Viviani MA, Arathoon E et al. New targets and delivery systems for antifungal therapy. Med. Mycol.38(Suppl. 1), 335–347 (2000).
   PubMed Web of Science ®Google Scholar
• Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy21(8 Pt 2), 133S–148S (2001).
   PubMed Web of Science ®Google Scholar
• McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs45, 2049–2068 (2005).
   Google Scholar
• Zaoutis TE, Benjamin DK, Steinbach W. Antifungal treatment in pediatric patients. Drug Resist. Update8, 235–245 (2005).
   PubMedGoogle Scholar
• Garnock-Jones KP, Kearn SJ. Caspofungin in pediatric patients with fungal infections. Pediatr. Drugs11, 259–269 (2009).
   PubMedGoogle Scholar
• Louie A, Deziel M, Liu W et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother.49, 5058–5068 (2005).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis HJ et al.In vitro susceptibilities of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol.46, 150–156 (2008).
   PubMed Web of Science ®Google Scholar
• VandenBussche HL, Van Loo DA. A clinical review of echinocandins in pediatric patients. Annal. Pharmacotherapy44, 166–177 (2010).
   PubMed Web of Science ®Google Scholar
• Odio CM, Araya R, Pinto LE et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J.23, 1093–1097 (2004).
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob. Agents Chemother.52, 321–328 (2008).
   PubMed Web of Science ®Google Scholar
• Bowman JC, Hicks PS, Kurtz MB et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatusin vitro. Antimicrob. Agents Chemother.46, 3001–3012 (2002).
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Chi J et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis.190, 1464–1471 (2004).
   PubMed Web of Science ®Google Scholar
• Douglas CM. Understanding the microbiology of the Aspergillus cell wall and the efficacy of caspofungin. Med. Mycol.44(Suppl.), 95–99 (2006).
   Web of Science ®Google Scholar
• Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J. Infect. Dis.182, 1791–1795 (2000).
   PubMed Web of Science ®Google Scholar
• Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob. Agents Chemother.51, 2587–2590 (2007).
   PubMed Web of Science ®Google Scholar
• Zeng J, Kamei K, Zheng Y, Nishimura K. Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents. Nippon Ishinkin Gakkai Zasshi45, 101–104 (2004).
   PubMedGoogle Scholar
• Groll AH, Walsh TJ. Antifungal agents. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases (6th Edition). Feigin RD, Demmler-Harrison GJ, Cherry JD, Kaplan SL (Eds). Saunders, Elsevier, PA, USA, 3271–3308 (2009).
   Google Scholar
• Shalit I, Shadkchan Y, Mircus G, Osherov N. In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp. Med. Mycol.47, 457–461 (2009).
   PubMed Web of Science ®Google Scholar
• Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. Isolates. Antimicrob. Agents Chemother.49, 3264–3273 (2005).
   PubMed Web of Science ®Google Scholar
• Hernandez S, Lopez-Ribot JL, Najvar LK et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother.49, 767–769 (2005).
   PubMedGoogle Scholar
• Chapeland-Leclerc F, Hennequin C, Papon N et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob. Agents Chemother.54, 1360–1362 (2010).
   PubMedGoogle Scholar
• Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother.53, 3690–3699 (2009).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol.46, 2620–2629 (2008).
   PubMed Web of Science ®Google Scholar
• Gardiner RE, Souteropoulos P, Park S, Perlin DS. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med. Mycol.43(Suppl. 1), S299–S305 (2005).
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob. Agents Chemother.51, 881–887 (2007).
   PubMed Web of Science ®Google Scholar
• Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against performed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother.46, 3634–3636 (2002).
   PubMed Web of Science ®Google Scholar
• Stevens DA, White TC, Perlin DS et al. Studies of the paradoxical effect of caspofungin at high concentrations. Diagn. Microbiol. Infect. Dis.51, 173–178 (2005).
   PubMed Web of Science ®Google Scholar
• Hadju R, Thompson R, Sundelof JG et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother.41, 2339–2344 (1997).
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Stoll BJ, Fanaroff AA et al. Neonatal candidiasis among extremely low birthweight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 and 22 months. Pediatrics117, 84–92 (2006).
   PubMed Web of Science ®Google Scholar
• Sáez-Llorens X, Macias M, Maiya P et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob. Agents Chemother.53, 869–875 (2009).
   PubMed Web of Science ®Google Scholar
• Groll AH, Gullick BM, Petraitiene R et al. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob. Agents Chemother.45, 596–600 (2001).
   PubMed Web of Science ®Google Scholar
• Stone JA, Holland SD, Wickersham PJ et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother.46, 739–745 (2002).
   PubMed Web of Science ®Google Scholar
• Stone JA, Xu X, Winchell GA et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob. Agents Chemother.48, 815–823 (2004).
   PubMed Web of Science ®Google Scholar
• Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int. J. Clin. Pract.55, 633–638 (2001).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother.49, 4536–4545 (2005).
   PubMed Web of Science ®Google Scholar
• Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporine A in patients with invasive fungal infections. Bone Marrow Transplant.34, 13–20 (2004).
   PubMed Web of Science ®Google Scholar
• Neely M, Jafri HS, Seibel N et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob. Agents Chemother.53, 1450–1458 (2009).
   PubMed Web of Science ®Google Scholar
• Koo A, Sung L, Allen U et al. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children. Pediatr. Infect. Dis. J.26, 854–856 (2007).
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Invest. Drugs10, 1545–1558 (2001).
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK. New antifungal agents under development in children. Curr. Opin. Infect. Dis.18, 484–489 (2005).
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Groll AH. Caspofungin in pediatric patients. Pediatric Health2, 677–685 (2008).
   Google Scholar
• Fisher BT, Zaoutis T. Caspofungin for treatment of pediatric fungal infections. Pediatr. Infect. Dis. J.27, 1099–1101 (2008).
   PubMedGoogle Scholar
• Groll AH, Attarbashi A, Schuster F et al. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J. Antimicrob. Chemother.57, 527–535 (2006).
   PubMed Web of Science ®Google Scholar
• Zaoutis T, Lehrnbecher T, Groll AH et al. Safety experience with caspofungin in pediatric patients. Pediatr. Infect. Dis. J.28, 1132–1135 (2009).
   PubMed Web of Science ®Google Scholar
• Mycamine package insert. Astellas Pharma, Deerfield, IL, USA (2008).
   Google Scholar
• Franklin JA, McCormick J, Flynn PM. Retrospective study of safety of caspofungin in immunocompromised pediatric patients. Pediatr. Infect. Dis. J.22, 747–749 (2003).
   PubMed Web of Science ®Google Scholar
• Merlin E, Galambrun C, Ribaud P et al. Efficacy and safety of caspofungin therapy in children with invasive fungal infections. Pediatr. Infect. Dis. J.25, 1186–1188 (2006).
   PubMed Web of Science ®Google Scholar
• Cesaro S, Giacchino M, Locatelli F et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect. Dis.7, 28 (2007).
   PubMed Web of Science ®Google Scholar
• Mrowczynski W, Wojtalik M. Caspofungin for Candida endocarditis. Pediatr. Infect. Dis. J.23, 376 (2004).
   PubMed Web of Science ®Google Scholar
• Wertz KK, Pretzlaff RK. Caspofungin in a pediatric patient with persistent candidemia. Pediatr. Crit. Care Med.5, 181–183 (2004).
   PubMedGoogle Scholar
• Castagnola E, Machetti M, Cappelli B et al. Caspofungin associated with amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukemia or undergoing allogeneic bone marrow transplant. Clin. Microbiol. Infect.10, 255–257 (2004).
   PubMed Web of Science ®Google Scholar
• Yalaz M, Akisu M, Hilmioglu S, Calkavur S, Cakmak B, Kultursay N. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicemia in an extremely low birth weight neonate. Mycoses49, 242–245 (2006).
   PubMed Web of Science ®Google Scholar
• Madero L, Sanchez de Toledo J, Castel V, Sevilla J, Gonzalez-Esteban J, Sanz-Rodriguez C. Compassionate use study of caspofungin in children with proven or suspected invasive mycosis or persistent febrile neutropenia. J. Chemother.21, 229–231 (2009).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Jafri HS, Huang LM et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida and Aspergillus infections in pediatric patients. Pediatrics123, 877–884 (2009).
   PubMed Web of Science ®Google Scholar
• Maertens JA, Madero L, Reilly AF et al. A randomized, double-blind, multicenter trial of caspofungin versus liposomal amphotericin B for empirical antifungal therapy of pediatric patients with persistent fever and neutropenia. Pediatr. Infect. Dis. J.29, 415–420 (2010).
   PubMed Web of Science ®Google Scholar
• Prasad PA, Coffin SE, Leckerman KH, Walsh TJ, Zaoutis TE. Pediatric antifungal utilization: new drugs, new trends. Pediatr. Infect. Dis. J.27, 1083–1088 (2008).
   PubMed Web of Science ®Google Scholar
• Hesseling M, Weindling M, Neal T. First reported use of caspofungin in an extremely low-birth-weight neonate. J. Matern. Fetal Neonatal Med.14, 212 (2003).
   PubMedGoogle Scholar
• Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J. Perinatol.25, 770–777 (2005).
   PubMedGoogle Scholar
• Odio CM, Castro CE VS Jr, Lazo JJ, Herrera ML. Caspofungin (CAS) therapy (Tx) for neonates (Ns) with invasive candidiasis (IC) cared for at intensive care units (ICU) (Abstract G-976). Presented at: The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007.
   Google Scholar
• Smith PB, Steinbach WJ, Cotton CM et al. Caspofungin for the treatment of azole resistant candidemia in a premature infant. J. Perinatol.27, 127–129 (2007).
   PubMed Web of Science ®Google Scholar
• Natale F, Castronovo A, Regoli D, De Curtis M, Manzoni P. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant. Pediatr. Infect. Dis. J.28, 452 (2009).
   PubMed Web of Science ®Google Scholar
• Elanjikal Z, Sorensen J, Schmidt H et al. Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. Pediatr. Infect. Dis. J.22, 653–656 (2003).
   PubMed Web of Science ®Google Scholar
• Vagace JM, Sanz-Rodriguez C, Casado M et al. Resolution of disseminated fusariosis in a child with acute leukemia treated with combined antifungal therapy: a case report. BMC Infect. Dis7, 40 (2007).
   PubMed Web of Science ®Google Scholar
• Haase R, Kreft B, Foell J, Kekulé AS, Merkel N. Successful treatment of Candida albicans septicemia in a preterm infant with severe congenital ichthyosis (Harlequin baby). Pediatr. Dermatol.26, 575–578 (2009).
   PubMedGoogle Scholar
• Ting JY, Chan S, Lung DS et al. Intra-abdominal Rhizopus microsporus infection successfully treated by combined aggressive surgical, antifungal, and iron chelating therapy. J. Pediatr. Hematol. Oncol.32, e238–e240 (2010).
   Google Scholar
• Cesaro S, Toffolutti T, Messina C et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycoses. Eur. J. Haematol.73, 50–55 (2004).
   PubMed Web of Science ®Google Scholar
• Castagnola E, Francheschi A, Natalizia AR, Montero E, Tuo P. Combined antifungal therapy for persistent central venous catheter-related candidemia in extremely low birth weight neonates. J. Chemother.21, 234–235 (2009).
   PubMed Web of Science ®Google Scholar